<?xml version="1.0" encoding="UTF-8"?><!--Transformation version 1.3--><legislativeDoc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://www.lexisnexis.com/xmlschemas/content/public/legislativedoc/1/" schemaVersion="1.0"><legislativeDocHead><citations><citeForThisResource citeDefinition="#7159#349#000054#     1#         3452#">Va. Code Ann. ยง 54.1-3452</citeForThisResource></citations><legislativeBodyInfo><jurisdiction><jurisSystem normalizedLongName="Virginia" normalizedShortName="VA"/></jurisdiction></legislativeBodyInfo></legislativeDocHead><legislativeDocBody><statute><level levelType="section"><anchor id="_54.1-3452"/><heading><desig>ยง 54.1-3452.</desig><title>Schedule IV</title></heading><level levelType="paragraph"><bodyText><p>The controlled substances listed in this section are included in Schedule IV unless specifically excepted or listed in another schedule:</p></bodyText><level levelType="paragraph"><anchor id="_1"/><heading><desig>1.</desig></heading><bodyText><p> Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>Alfaxalone (5[alpha]-pregnan-3[alpha]-ol-11,20-dione), previously spelled "alphaxalone," including its salts, isomers, and salts of isomers;</p><p><pre/>Alprazolam;</p><p><pre/>Barbital;</p><p><pre/>Bromazepam;</p><p><pre/>Camazepam;</p><p><pre/>Carisoprodol;</p><p><pre/>Chloral betaine;</p><p><pre/>Chloral hydrate;</p><p><pre/>Chlordiazepoxide;</p><p><pre/>Clobazam;</p><p><pre/>Clonazepam;</p><p><pre/>Clorazepate;</p><p><pre/>Clotiazepam;</p><p><pre/>Cloxazolam;</p><p><pre/>Delorazepam;</p><p><pre/>Diazepam;</p><p><pre/>Dichloralphenazone;</p><p><pre/>Estazolam;</p><p><pre/>Ethchlorvynol;</p><p><pre/>Ethinamate;</p><p><pre/>Ethyl loflazepate;</p><p><pre/>Fludiazepam;</p><p><pre/>Flunitrazepam;</p><p><pre/>Flurazepam;</p><p><pre/>Fospropofol;</p><p><pre/>Halazepam;</p><p><pre/>Haloxazolam;</p><p><pre/>Ketazolam;</p><p><pre/>Loprazolam;</p><p><pre/>Lorazepam;</p><p><pre/>Lormetazepam;</p><p><pre/>Mebutamate;</p><p><pre/>Medazepam;</p><p><pre/>Methohexital;</p><p><pre/>Meprobamate;</p><p><pre/>Methylphenobarbital;</p><p><pre/>Midazolam;</p><p><pre/>Nimetazepam;</p><p><pre/>Nitrazepam;</p><p><pre/>Nordiazepam;</p><p><pre/>Oxazepam;</p><p><pre/>Oxazolam;</p><p><pre/>Paraldehyde;</p><p><pre/>Petrichloral;</p><p><pre/>Phenobarbital;</p><p><pre/>Pinazepam;</p><p><pre/>Prazepam;</p><p><pre/>Quazepam;</p><p><pre/>Suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1 -yl][5-methyl-2- (2H-1,2,3-triazol-2-yl) phenyl]methanone), including its salts, isomers, and salts of isomers;</p><p><pre/>Temazepam;</p><p><pre/>Tetrazepam;</p><p><pre/>Triazolam;</p><p><pre/>Zaleplon;</p><p><pre/>Zolpidem;</p><p><pre/>Zopiclone.</p></bodyText></level></level><level levelType="paragraph"><anchor id="_2"/><heading><desig>2.</desig></heading><bodyText><p> Any compound, mixture or preparation which contains any quantity of the following substances including any salts or isomers thereof:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>Fenfluramine;</p><p><pre/>Lorcaserin.</p></bodyText></level></level><level levelType="paragraph"><anchor id="_3"/><heading><desig>3.</desig></heading><bodyText><p> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>Cathine (+)-norpseudoephedrine;</p><p><pre/>Diethylpropion;</p><p><pre/>Fencamfamin;</p><p><pre/>Fenproprex;</p><p><pre/>Mazindol;</p><p><pre/>Mefenorex;</p><p><pre/>Modafinil;</p><p><pre/>Phentermine;</p><p><pre/>Pemoline (including organometallic complexes and chelates thereof);</p><p><pre/>Pipradrol;</p><p><pre/>Sibutramine;</p><p><pre/>SPA (-)-1-dimethylamino-1, 2-diphenylethane.</p></bodyText></level></level><level levelType="paragraph"><anchor id="_4"/><heading><desig>4.</desig></heading><bodyText><p> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxy butane);</p><p><pre/>Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit;</p><p><pre/>2-[(dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol, its salts, optical and geometric isomers, and salts of such isomers, including tramadol.</p></bodyText></level></level><level levelType="paragraph"><anchor id="_5"/><heading><desig>5.</desig></heading><bodyText><p> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including their salts:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>Butorphanol (including its optical isomers);</p><p><pre/>Eluxadoline (including its optical isomers and its salts, isomers, and salts of isomers);</p><p><pre/>Pentazocine.</p></bodyText></level></level><level levelType="paragraph"><anchor id="_6"/><heading><desig>6.</desig></heading><bodyText><p> The Board may except by regulation any compound, mixture, or preparation containing any depressant substance listed in subdivision 1 from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.</p></bodyText></level></level><history><historyGroup groupType="history-citation"><historyItem><bodyText><p>1972, c. 798, ยง 54-524.84:10; 1976, c. 614; 1977, c. 302; 1978, c. 705; 1979, c. 387; 1982, c. 505; 1986, c. 463; 1988, cc. 283, 765; <citation normalizedCite="1992 VA CH 737"><content><span normalizedCite="1992 Va. Ch. 737">1992, c. 737<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#1992#000737#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="1994 VA CH 763"><content><span normalizedCite="1994 Va. Ch. 763">1994, c. 763<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#1994#000763#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="1998 VA CH 105"><content><span normalizedCite="1998 Va. Ch. 105">1998, c. 105<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#1998#000105#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="1999 VA CH 605"><content><span normalizedCite="1999 Va. Ch. 605">1999, c. 605<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#1999#000605#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2000 VA CH 135"><content><span normalizedCite="2000 Va. Ch. 135">2000, c. 135<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2000#000135#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2003 VA CH 640"><content><span normalizedCite="2003 Va. Ch. 640">2003, c. 640<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2003#000640#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2006 VA CH 346"><content><span normalizedCite="2006 Va. Ch. 346">2006, c. 346<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2006#000346#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2010 VA CH 423"><content><span normalizedCite="2010 Va. Ch. 423">2010, c. 423<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2010#000423#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2012 VA CH 540"><content><span normalizedCite="2012 Va. Ch. 540">2012, c. 540<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2012#000540#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2014 VA CH 74"><content><span normalizedCite="2014 Va. Ch. 74">2014, c. 74<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2014#000074#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2015 VA CH 303"><content><span normalizedCite="2015 Va. Ch. 303">2015, c. 303<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2015#000303#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2016 VA CH 499"><content><span normalizedCite="2016 Va. Ch. 499">2016, c. 499<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2016#000499#"/></locatorKey></locator></span></content></citation>.</p></bodyText></historyItem></historyGroup></history></level></statute></legislativeDocBody><metadata><dc:metadata xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:identifier identifierScheme="PGUID">urn:contentItem:5K0Y-PTB0-004G-K2CT-00000-00</dc:identifier><dc:source sourceScheme="productContentSetIdentifier">10816</dc:source><dc:date dateType="last-updated">2016-06-15</dc:date></dc:metadata><publicationInfo><publicationName>CODE OF VIRGINIA </publicationName><copyright>Copyright ยฉ 2016  by Matthew Bender &amp; Company, Inc. a member of the LexisNexis Group. All rights reserved</copyright></publicationInfo><hierarchy><hierarchyLevel levelType="title"><heading><desig>TITLE 54.1.</desig><title>PROFESSIONS AND OCCUPATIONS</title></heading><hierarchyLevel levelType="subtitle"><heading><desig>SUBTITLE III.</desig><title>PROFESSIONS AND OCCUPATIONS REGULATED BY BOARDS WITHIN THE DEPARTMENT OF HEALTH PROFESSIONS</title></heading><hierarchyLevel levelType="chapter"><heading><desig>CHAPTER 34.</desig><title>DRUG CONTROL ACT</title></heading><hierarchyLevel levelType="article"><heading><desig>ARTICLE 5.</desig><title>STANDARDS AND SCHEDULES</title></heading></hierarchyLevel></hierarchyLevel></hierarchyLevel></hierarchyLevel></hierarchy><classificationGroup classificationScheme="indexing-terms"><classification classificationScheme="legal"><classificationItem><className>Business &amp; Corporate Compliance</className><classCode>Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI7cGFyZW50Z3VpZD0</classCode><classificationItem score="90"><className>Businesses &amp; Corporations</className><classCode>Z3VpZD11cm46dG9waWM6QjA4OEVGODBENzY4NDcxM0IyQzA1OTEwQzVDODRBOUE7cGFyZW50Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI</classCode></classificationItem></classificationItem></classification></classificationGroup></metadata></legislativeDoc>